VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs MRNA 1215 (Primary)
- Indications Nipah virus infections
- Focus Adverse reactions; First in man
- 24 Sep 2024 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 24 Jun 2024 to 1 Oct 2024.
- 12 Sep 2023 Planned primary completion date changed from 24 Jun 2024 to 1 Oct 2024.